A. Publications


5. Hess PL, Kennedy K, Cowherd M, Virani SS, Masoudi FA, Navar AM, Yeh RW, Ho PM, Maddox TM. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: an NCDR Research to Practice (R2P) project. *Am Heart J* 2018;195:151–152.


phospholipase A2 and risk of incident peripheral arterial disease: findings from the Atherosclerosis Risk in Communities study (ARIC). *Atherosclerosis* 2017;268:12–18.


59. Chelu MG, Li N. Biomarkers (plasma trimethylamine-N-oxide) to predict atrial fibrillation: are we there yet? *Int J Cardiol* 2018 [Epub ahead of print].


64. Navaneethan SD, Virani SS. Omega-3 fatty acids (fish oil) supplementation and albuminuria: not a slam dunk. J Am Heart Assoc 2017;6:e006020.


99. Ridker PM, MacFadyen JG, Everett BM, Libby P, Stojakovic T, Pilbrow AP, Cameron VA, Richards AM, Doughty RN, Gong Y, Cooper-DeHoff R, Johnson J, Scholz M, Beutner F, Thiery J,


B. Awards and honors

1. Ballantyne: Houston Chronicle Top Doctors 2017
2. Ballantyne: Castle Connaly Top Doctors: Southeast Texas, Castle Connaly Medical Ltd., 2017
3. Ballantyne: Castle Connaly Top Doctors in Texas for the Speciality of Cardiovascular Disease, Castle Connally Medical Ltd., 2017
4. Ballantyne: Castle Connaly Top Doctors in America, Castle Connally Medical Ltd., 2018
5. **Ballantyne**: Selected by his peers for inclusion in Best Doctors in America®, Best Doctors, Inc., Aiken, South Carolina, 2018
6. **Ballantyne**: 2017 Highly Cited Researcher presented by Clarivate Analytics, Web of Science, top 1% of researchers most cited
7. **Entman**: International Academy of Cardiovascular Sciences Lifetime Achievement Award in Cardiovascular Science, Medicine and Surgery, August 2017
8. **Li**: University of Houston Teaching Excellence Award for Group Teaching, 2017–2018
9. **Virani**: Norton Rose Fulbright Faculty Excellence Award, Development of Enduring Educational Materials, Baylor College of Medicine
10. **Virani**: Inducted into Best Doctors database

C. **Professional organization/association offices held**

1. **Ballantyne**: Chair, LDL: Address the Risk Think Tank, American College of Cardiology
2. **Ballantyne**: Writing Committee, Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk, American College of Cardiology
3. **Ballantyne**: Board, American Society for Preventive Cardiology
4. **Ballantyne**: Board, National Lipid Association
5. **Ballantyne**: Scientific Meeting Committee, National Lipid Association
6. **Ballantyne**: Co-chair, Project Review Committee, National Lipid Association
7. **Brunner**: Member, Grant Peer Review Committee, Innovative Project Award (IPA) Committee, American Heart Association
8. **Jones**: Chief Science Officer, National Lipid Association
9. **Virani**: Chair, Leadership Council and Council for the Prevention of Cardiovascular Disease, American College of Cardiology
10. **Virani**: Chair, Research and Publications Committee, PINNACLE Registry, National Cardiovascular Data Registry, American College of Cardiology
11. **Virani**: Member, LDL: Address the Risk Think Tank, American College of Cardiology
12. **Virani**: Member, Guideline Tool Work Group, 2018 ACC/AHA Cholesterol Guideline, American College of Cardiology
13. **Virani**: Member, Research to Practice (R2P) Initiative Work Group, National Cardiovascular Data Registry, American College of Cardiology
14. **Virani**: Topic Coordinator (Prevention), Annual Scientific Session Program Committee, American College of Cardiology
15. **Virani**: Chair, Heart Disease and Stroke Statistics Committee, American Heart Association
16. **Virani**: Member, EPI Leadership Committee, Council on Epidemiology and Prevention, American Heart Association
17. **Virani**: Board of Directors, American Society of Preventive Cardiology
18. **Wu**: Member, Grant Peer Review Committee, Lipids BSc 2 Committee, American Heart Association

D. **Editorial board memberships and editorial positions**

1. **Ballantyne**: Editorial Director, lipidsonline.org
2. **Ballantyne**: Editorial Board, *Circulation*
3. **Ballantyne**: Editorial Board, *Clinical and Translational Science*
4. **Ballantyne**: Editorial Board, *Current Cardiology Reviews*
5. **Ballantyne**: Editorial Board, *Future Lipidology*
6. **Cruz**: Editorial Board, *Thrombosis & Haemostasis: Research*
7. **Foreyt**: Editorial Board, *American Journal of Health Behavior*
8. **Foreyt**: Editorial Board, *American Journal of Health Promotion*
10. **Foreyt**: Editorial Board, *Childhood Obesity*
11. **Foreyt**: Editorial Board, *Nutrition Today*
12. **Foreyt**: Editorial Board, *Obesity and Weight Management*
13. **Foreyt**: Editorial Board, *Obesity Research and Clinical Practice*
14. **Jones**: Associate Editor, *Journal of Clinical Lipidology*
15. **Pi**: Guest Editor, *Oxidative Medicine and Cellular Longevity*
16. **Pi**: Review Editor, *Arteriosclerosis, Thrombosis and Vascular Biology*
17. **Pi**: Review Editor, *Frontiers*
18. **Pi**: Review Editor, *Journal of Molecular and Cellular Cardiology*
19. **Pi**: Review Editor, *Nature Communications*
20. **Virani**: Associate Editor, Innovations, ACC.org
21. **Virani**: Editorial Team Member and Chair for Digital Strategy, Cardiovascular Prevention Section, ACC.org (educational web portal for the American College of Cardiology)
22. **Virani**: Advisory Board, *Advances in Therapy*
23. **Virani**: Guest Editor, *Circulation*
24. **Virani**: Editorial Board, *Circulation*
25. **Virani**: Section Editor, "Coronary Heart Disease," *Current Atherosclerosis Reports*
26. **Virani**: Associate Editor, *Journal of Clinical Lipidology* (Section specialty: Cardiovascular Outcomes and Guidelines)
27. **Virani**: Associate Editor, *Global Heart* (Official Journal of the World Heart Federation)
28. **Wu**: Guest Associate Editor, *Frontiers in Immunology* (T cell biology in adipose tissue)
29. **Wu**: Editorial Board, *Archives of Inflammation*
30. **Wu**: Editorial Board, *International Journal of Hematology Research*
31. **Wu**: Editorial Board, *Journal of Pediatric Endocrinology*
32. **Wu**: Editorial Board, *JSM Atherosclerosis*
33. **Wu**: Editorial Board, *SM Journal of Endocrinology and Metabolism*

**E. Other significant accomplishments**

1. **Brunner**: Reviewer, Biomedical Imaging Technology Study Section–A, Center for Scientific Review, NIH, Bethesda, MD
2. **Brunner**: Reviewer and "Application Chair," ZRG1 MOSS-D (82) A NIH study Section (Musculoskeletal, Oral, Skin, Rheumatology and Rehab Sciences [R15])
3. **Brunner**: Invited Keynote Speaker, "Skeletal Calf Muscle Perfusion Measurement To Assess Peripheral Arterial Disease," 10th European Symposium Of Vascular Biomaterials Strasbourg, France
4. **Brunner**: Invited Guest Speaker, Special Seminar on Magnetic Resonance Imaging in Peripheral Artery Disease, Penn State Heart and Vascular Institute, Penn State Health Milton S. Hershey Medical Center, Hershey, PA
5. **Brunner**: Invited Speaker, "Inflammation, Microvascular Perfusion, and Peripheral Arterial Disease," George and Angelina Kostas Research Center for Cardiovascular Nanomedicine, Annual International Meeting, Houston, TX
6. **Brunner**: Invited Presenter, "Inflammation, Microvascular Perfusion and Peripheral Arterial Disease," American Heart Association Reverse Site Visit as one of the 9
7. **Brunner**: Invited Presenter, "Advanced Physics, Fourier Transformation Parallel Imaging, and MRI Safety," Houston Methodist Cardiovascular Magnetic Resonance Workshop, DeBakey Institute for Cardiovascular Education & Training, Houston Methodist Hospital, Houston, TX

8. **Brunner**: Didactic Lectures, Cardiovascular sciences graduate course (GS-CS-411)—Cardiovascular Physiology, and Structural Basis of Human Diseases (GS-SB-423), BCM

9. **Brunner**: Poster Judge, 3rd Annual VA Research Poster Session. Michael E. DeBakey VA Medical Center, Houston, TX

10. **Cruz**: Invited lecture, "A Novel Target to Prevent Microvascular Thrombosis and Multiple Organ Dysfunction Syndrome in Sepsis," Microbiology & Immunology, UTMB

11. **Cruz**: Invited lecture, "Novel Targets to Prevent Microvascular Thrombosis in Sepsis," CVRI seminar series, BCM

12. **Li**: Ad hoc reviewer, 2018 NIH ESTA Study Section

13. **Li**: Ad hoc reviewer, 2017 Farouk Jabre Research Proposal

14. **Li**: Invited lecture, "The inflammasome in AF," Heart Failure Association Winter Meeting on Translational Heart Failure Research 2018, Les Diablerets, Switzerland

15. **Li**: Invited lecture, "Emerging role of the inflammasome as novel target in atrial fibrillation therapy," American Heart Association Scientific Session 2017, Anaheim, CA

16. **Li**: Invited lecture, "Role of Cardiac Inflammasome in the Pathogenesis of Atrial Fibrillation," IMBS 2018 Research Conference and Retreat, BCM

17. **Li**: Invited lecture, "Emerging Role of Cardiac Inflammasome In the Development of Atrial Fibrillation," CVRI seminar series, BCM

18. **Li**: Invited conference moderator, Ion Channels and Arrhythmias session, American Heart Association Basic Cardiovascular Sciences (BCVS) Council Scientific Sessions 2017, Portland, OR


20. **Pi**: Invited lecture, "The role of vascular endothelium in metabolic health," Texas Heart Institute seminar series

21. **Pi**: Course organizer, TBMM graduate program Bench to Bedside Series, Term 3: Current topics in translational cardiovascular medicine

22. **Pi**: Seminar host, TBMM graduate program Bench to Bedside Series. "Ahoy CRISPR" presented by Dr. Joseph M. Miano, University of Rochester

23. **Pi**: Poster judge, CVRI 2018 Symposium, BCM

24. **Pi**: Grant proposal reviewer, CVRI Pilot Awards, BCM

25. **Pi**: Reviewer of graduate student candidates, Molecular Physiology & Biophysics Graduate Program, BCM

26. **Pi**: Member of Graduate student committee for Nirva Mumcuyan, Developmental Biology Program, BCM

27. **Virani**: Invited speaker, Global Cardiovascular Disease Prevention webinars in Indonesia, Malaysia, Vietnam, and UAE

28. **Wu**: Member, NIH/NIGMS SCORE Grant Review Panel

29. **Wu**: Member, American Heart Association Grant Peer Review Committee, Lipids BSc Committee

30. **Wu**: Member, Immunology Graduate Program Qualifying Exam Committee, BCM

31. **Wu**: Member, Immunology Graduate Admission Committee, BCM

32. **Wu**: English language interviewer, J1 visa candidates, BCM

33. **Wu**: Poster judge, CVRI 2018 Symposium, BCM
F. Grants

1. **Ballantyne (co-PI):** Profiling Cardiovascular Events and Biomarkers in the Very Old to Improve Personalized Approaches for the Prevention of Cardiac and Vascular Disease; NIH/NHLBI (R01); annual direct costs $549,802 (09/01/2016–08/31/2020)

2. **Ballantyne (coinvestigator):** Atherosclerosis Risk in Communities (ARIC) Study–Field Centers; NIH; annual direct costs $311,673 (11/15/2016–11/14/2021)

3. **Ballantyne (coinvestigator):** Monocyte Activation and the Role of CD11c in Obesity-Linked Metabolic Syndrome; NIH/NHLBI (R01); annual direct costs $241,769 (04/01/2015–03/31/2020)

4. **Ballantyne (coinvestigator):** Diabetes and Prediabetes in Older Adults; NIH/NIDDK (R01); annual direct costs $36,371 (01/01/2016–12/31/2020)

5. **Ballantyne (coinvestigator):** miRNAs, Whole Diet, and Coronary Heart Disease; NIH/NHLBI (R56); total direct costs $12,147 (09/01/2016–08/31/2018)

6. **Ballantyne (coinvestigator):** Comparative Effectiveness of Physicians versus Non-physicians for the Delivery of Outpatient Diabetes Care: Implications for Access to Care under the Affordable Care Act; American Diabetes Association; total direct costs: $486,957 (01/01/2014–12/31/2017)

7. **Ballantyne (PI):** The Familial Hypercholesterolemia Foundation Cascade-FH Registry; Duke University; total direct costs $20,000 (07/01/2014–06/30/2019)

8. **Ballantyne (PI):** Measurement of Galectin-3 at Visit 4 and Visit 5 for the Full ARIC Cohort; Abbott Laboratories; total direct costs $31,500 (03/14/2014–07/31/2018)

9. **Ballantyne (PI):** hsTroponin Screening at Visit 4 and Visit 5 for the Full ARIC Cohort; Abbott Laboratories; total direct costs $371,965 (05/12/2014–05/11/2019)

10. **Ballantyne (PI):** A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD); Akcea Therapeutics; total direct costs $172,510 (02/28/2017–02/27/2020)

11. **Ballantyne (PI):** A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients with Hypertriglyceridemia and Established Cardiovascular Disease; Akcea Therapeutics; total direct costs $206,886 (03/08/2018–03/07/2021)

12. **Ballantyne (PI):** A Multicenter, Controlled, Open-Label Extension (OLE) Study to Assess the Long-Term Safety and Efficacy of AMG-145; Amgen, Inc; total direct costs $43,965 (06/01/2013–02/08/2018)

13. **Ballantyne (PI):** GAUSS-3A—Double-Blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of AMG 145, Compared with Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of an HMG-CoA Reductase Inhibitor due to Muscle Related Side Effects; Amgen, Inc; total direct costs $60,085 (02/18/2014–03/21/2018)

14. **Ballantyne (PI):** A Multicenter, Open-Label, Single-Arm, Extension Study to Assess Long-Term Safety of Evolocumab Therapy in Patients with Clinically Evident Cardiovascular Disease; Amgen Inc; total direct costs $45,670 (08/17/2016–12/31/2021)

15. **Ballantyne (PI):** A Randomized, Double-Blind, Placebo-Controlled, Multicenter Long-
Term Safety and Tolerability Study of ETC 1002 in Patients with Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy; Esperion Therapeutics; total direct costs $62,963 (06/27/2016–06/29/2018)

16. **Ballantyne (PI):** A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant; Esperion Therapeutics; total direct costs $40,614 (05/17/2017–04/30/2020)

17. **Ballantyne (PI):** A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of bempedoic acid (ETC1002) 180 mg/day as add-on to ezetimibe therapy in patients with elevated LDL-C; Esperion Therapeutics; total direct costs $29,253 (06/07/2017–04/25/2018)

18. **Ballantyne (PI):** A Randomized, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 mg + Ezetimibe 10 mg Fixed-dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated Statin Therapy; Esperion Therapeutics; total direct costs $21,194 (11/29/2017–11/17/2018)

19. **Ballantyne (PI):** A Multicenter Open-Label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 mg; Esperion Therapeutics; total direct costs $22,400 (08/07/2017–12/31/2019)


21. **Brunner (PI):** Microvascular Perfusion Assessment of Ischemic Diabetic Ulcers Using MRI; NIH/NHLBI (K25); annual direct costs $154,958 (12/01/2014–12/31/2019)

22. **Brunner (PI):** MRI Based Calf Muscle Perfusion to Assess Patients with Symptomatic PAD; NIH/NHLBI (R01); annual direct costs $350,417 (08/01/2017–07/31/2022)

23. **Brunner (coinvestigator):** Biomarker Guided Therapies in Stage A/B Heart Failure; VA Office of Research and Development; annual direct costs $14,189 (04/01/2014–03/31/2019)

24. **Cieslik (co-PI):** Trafficking Leukocytes in the Aging Mouse Heart: in Vivo MRI and Flow Cytometry; BCM Cardiovascular Research Institute Pilot Award (09/01/2017–06/30/2018)

25. **Cieslik (coinvestigator):** Role of Blood-Borne Fibroblast Precursors in Ischemic Cardiomyopathy; NIH/NHLBI (R01); annual direct costs $250,000 (07/01/2007–11/30/2017)

26. **Cieslik (PI):** A Spontaneous Mutation in Nnt Gene Promotes Cardiac Fibrosis in the Aging Heart; The Medallion Foundation; total direct costs $50,000 (07/01/2015–12/31/2018)

27. **Cruz (multi-PI):** Microvascular Thrombosis in Systemic Inflammation; NIH/NIGMS (R01); annual direct costs $220,000 (09/25/2014–05/31/2019)

28. **Cruz (co-PI):** Role of Vimentin in Thrombosis and Stroke; NIH/NINDS (R01); annual direct costs $381,958 (09/01/2016–05/31/2021)

29. **Entman (PI):** Role of Blood-Borne Fibroblast Precursors in Ischemic Cardiomyopathy; NIH/NHLBI (R01); annual direct costs $250,000 (07/01/2007–11/30/2017)

30. **Entman (PI):** Researching the Aging Heart; The Curtis and Doris K. Hankamer Foundation; annual direct costs $40,000 (01/01/2001–12/31/2018)
31. **Foreyt (PI):** Study of Health Outcomes of Weight-Loss (Look AHEAD) Trial; NIH/NIDDK (U01); annual direct costs $152,265 (09/01/1999–01/31/2019)

32. **Foreyt (PI):** Vitamin D to Prevent Type 2 Diabetes (D2d Study); NIH/NIDDK (U01); annual direct costs $45,309 (06/01/2013–01/31/2019)

33. **Hoogeveen (coinvestigator):** Atherosclerosis Risk in Communities (ARIC) Study—Field Centers; NIH/NHLBI; annual direct costs $311,673 (11/15/2016–11/14/2021)

34. **Hoogeveen (coinvestigator):** Diabetes and Pre-diabetes in Older Adults; NIH/NIDDK (R01); total direct costs $200,000 (09/01/2016–12/31/2020)

35. **Hoogeveen (coinvestigator):** Endogenous Hormones and Postmenopausal Breast Cancer: Etiologic Insights and Improving Risk Prediction; NIH/NCI; annual direct costs $76,772 (06/15/2017–03/31/2022)

36. **Hoogeveen (PI):** Relation of Lipoprotein(a) and Small Dense LDL-C (sdLDL-C) to Incident CHD and Stroke: the ARIC Study; Denka Seiken Co, Ltd; annual direct costs $18,021 (10/01/2010–12/31/2017)

37. **Hoogeveen (PI):** Relationship of Small-Dense LDL Cholesterol (sdLDL-C) and Lp(a) with Progression of Atherosclerosis in the Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin versus Atorvastatin (SATURN) Trial; Denka Seiken Co, Ltd (11/01/2013–12/31/2017)

38. **Hoogeveen (PI):** Lipoprotein Subfractions Study: the ARIC Study; Denka Seiken Co, Ltd; annual direct costs $56,750 (11/01/2015–08/31/2018)

39. **Jones:** A Multi-center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA Intervention Trial); Amarin Pharmaceuticals; total direct costs $25,000 (06/01/2012–12/31/2018)

40. **Li (PI):** Inflammasome Mediated Pathogenesis of Atrial Fibrillation; NIH/NHLBI (R56); annual direct costs $250,000 (09/01/2016–08/31/2018)

41. **Li (PI):** The Role of Inflammasome in the Pathogenesis of Atrial Fibrillation; NIH/NHLBI (R01); annual direct costs $379,069 (09/01/2017–06/30/2021)

42. **Li (PI):** Transcriptional Regulation of Ryanodine Receptor 2 in Atrial Fibrillation; American Heart Association Scientist Development Grant; annual direct costs $379,069 (09/01/2017–06/30/2021)

43. **Li (coinvestigator):** Novel Roles of FE2+, 2-Oxoglutarate-Dependent Dioxygenases in Cardiac Function; NIH/NHLBI (R01); annual direct costs $250,000 (09/01/2015–08/31/2020)

44. **Li (coinvestigator):** Pitx2 in Atrial Fibrillation; NIH/NHLBI (R01); annual direct costs $327,304 (02/01/2018–02/28/2023)

45. **Nambi (PI):** Biomarker Guided Therapies in Stage A/B Heart Failure; VA Office of Research and Development; annual direct costs $14,189 (04/01/2014–03/31/2019)

46. **Nambi (PI):** TIMI 55/REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid-Modification): A Large Scale, Randomized, Placebo-Controlled Trial of the Clinical Effects of Anacetrapib among People with Established Vascular Disease; Brigham and Women's Hospital; total direct costs $150,000 (11/01/2011–02/28/2019)

47. **Pi (PI):** LRP1 and Endothelial Function; NIH/NHLBI (R01); annual direct costs $250,000 (08/01/2013–05/31/2019)

48. **Pi (PI):** Signaling in Endothelial Growth and Angiogenesis; NIH/NHLBI (R01); annual direct costs $250,000 (12/18/2013–12/31/2018)
49. **Trial (coinvestigator):** Role of Blood-Borne Fibroblast Precursors in Ischemic Cardiomyopathy; NIH/NHLBI (R01); annual direct costs $250,000 (07/01/2007–11/30/2017)

50. **Vijayan (PI):** Serine/Threonine Phosphatases and Platelet Physiology; NIH/NHLBI (R01); annual direct costs $250,000 (03/01/2013–02/28/2019)

51. **Vijayan (multi-PI):** Microvascular Thrombosis in Systemic Inflammation; NIH/NIGMS (R01); annual direct costs $220,000 (09/25/2014–05/31/2019)

52. **Vijayan (PI of subcontract to Baylor College of Medicine):** Aspirin-PC for Chemoprevention of Colorectal Cancer; NIH/NCI (R42); annual direct costs $86,000 (05/01/2017–04/30/2019)

53. **Vijayan (PI):** PP2B Modulates RhoA Activation and Platelet Function by Targeting RhoGDI; American Heart Association; annual direct costs $70,000 (07/01/2017–06/30/2019)

54. **Virani (PI):** Comparative Effectiveness of Physicians versus Non-physicians for the Delivery of Outpatient Diabetes Care: Implications for Access to Care under the Affordable Care Act; American Diabetes Association; total direct costs: $486,957 (01/01/2014–12/31/2017)

55. **Virani (PI):** Determining and Targeting Reasons for Low Statin Use to Improve Guideline-Concordant Statin Therapy in High-Risk Patients; VA Merit Award; total direct costs: $1,097,703 (07/01/2017–06/30/2021)

56. **Wu (PI):** Monocyte Activation and the Role of CD11c in Obesity-Linked Metabolic Syndrome; NIH/NHLBI (R01); annual direct costs $241,769 (04/01/2015–03/31/2020)

57. **Wu (PI):** ApoCIII, Triglyceride-Rich Lipoproteins and Atherogenesis; American Heart Association; total direct costs $140,000 (07/01/2016–06/30/2019)

58. **Wu (PI):** Macrophage/Dendritic Cell Activation and Inflammation in Diet-Induced Obesity; American Diabetes Association; annual direct costs $104,546 (01/01/2017–12/31/2019)

59. **Wu (co-PI):** Imaging Monocyte Tracking into Atherosclerosis and Adipose Tissue in Mice; BCM Cardiovascular Research Institute Pilot Award; total direct costs $15,000 (09/01/2017–06/30/2018)

60. **Xie (PI):** Novel Roles of Fe2+, 2-Oxoglutarate-Dependent Dioxygenases in Cardiac Function; NIH/NHLBI (R01); annual direct costs $250,000 (09/01/2015–08/31/2020)

61. **Xie (coinvestigator):** LRP1 and Endothelial Function; NIH/NHLBI (R01); annual direct costs $250,000 (08/01/2013–05/31/2019)

62. **Xie (coinvestigator):** Signaling in Endothelial Growth and Angiogenesis; NIH/NHLBI (R01); annual direct costs $250,000 (12/18/2013–12/31/2018)